Inotuzumab Ozogamicin (CD22) 抗

Inotuzumab Ozogamicin (CD22) 抗体, 单克隆，Inotuzumab Ozogamicin (CD22) Antibody, Monoclonal，Inotuzumab Ozogamicin (CD22) 抗体, 单克隆,Inotuzumab Ozogamicin (CD22) Antibody, Monoclonal

产品名称：Inotuzumab Ozogamicin (CD22) 抗体, 单克隆-Inotuzumab Ozogamicin (CD22) Antibody, Monoclonal

产品货号：PSI-10-276-0.1mg

产品规格：0.1mg

背景资料：Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent 4. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of fully remission with no evidence of disease in comparison to patients receiving alternative chemotherapy 5.

保存建议：Inotuzumab Ozogamicin (CD22) 抗体, 单克隆-Inotuzumab Ozogamicin (CD22) Antibody, MonoclonalStore at -80℃

应用类型：

点击：Inotuzumab Ozogamicin (CD22) 抗体, 单克隆-Inotuzumab Ozogamicin (CD22) Antibody, Monoclonal查看更详细产品说明，更多应用、储存、价格、货期等信息请垂询艾美捷科技有限公司。更多ProSci公司特色试剂盒、特色抗体以及特色试剂等产品评论，请点击查看艾美捷特色产品中心。